MetaCap

MannKind Corporation (MNKD)

NASDAQ: MNKDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.85-0.10 (-2.53%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MNKD stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.24
52-week range
2.23 – 6.51
Day range
3.83 – 4.08
Volume / Avg
4.18M / 3.96M
Beta
—

52-week range

$2.23$6.51

MNKD stock today

On Nov 20, MNKD ended the session at $3.85, shedding $0.10 (2.53%), versus the S&P 500's 3.70% decline. At this level, MNKD sits in the middle of its 52-week range of $2.23 to $6.51: 40.9% below the high, set on Jan 8, 2026 and 72.6% above the low. MNKD is down 32.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 23.5%.

MannKind has posted a net loss over the last twelve months (EPS of -$0.24), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About MannKind

Company profile

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Michael E. Castagna Pharm.D.
Headquarters
Danbury, CT
Employees
591
IPO year
2004

Financial highlights

Full financials

In fiscal 2025, MannKind generated $349.0 million in revenue, up 22.2% from fiscal 2024, its 8th consecutive year of revenue growth. Net income was $5.9 million (-78.7% year over year), for a net margin of 1.7% versus a median of -87.6% in the prior 5 years. Gross margin was 92.3% (down from 93.9%) and operating margin 11.1%.

MannKind annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$348.97M$285.50M$198.96M$99.77M$75.44M
Growth+22.23%+43.50%+99.42%+32.25%+15.81%
Net income$5.86M$27.59M$-11.94M$-87.40M$-80.93M
EPS (diluted)$0.02$0.10$-0.04$-0.34$-0.32

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$8.33+116.36%

  • Strong buy 0
  • Buy 8
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $13.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.03 vs $-0.08
Surprise
+137.50%

MNKD news

All MNKD news

MannKind peers

Health Care sector
MNKD peer companies
CompanyPrice% ChgMarket capCompare
SLNSilence Therapeutics Plc American Depository Share19.810.00%$1.23Bvs MNKD
GENBGenerate Biomedicines Inc.9.54-8.00%$1.23Bvs MNKD
OCULOcular Therapeutix Inc.5.57-4.95%$1.23Bvs MNKD
LBRXLB Pharmaceuticals Inc38.85-2.97%$1.26Bvs MNKD
AVLNAvalyn Pharma Inc.28.40-1.05%$1.26Bvs MNKD
MLYSMineralys Therapeutics Inc.13.66-3.53%$1.21Bvs MNKD
AMPHAmphastar Pharmaceuticals Inc.28.25+0.50%$1.20Bvs MNKD
GHRSGH Research PLC17.53-5.55%$1.20Bvs MNKD

Indexes, lists and sector

MannKind stock FAQ

What is MannKind's stock price today?

MNKD last traded at $3.85 as of Nov 20, 4:00 PM EST, down 2.53% on the day. Prices are delayed at least 15 minutes.

Does MannKind pay a dividend?

No. MannKind does not currently pay a regular cash dividend.

Who is MannKind's CEO?

Dr. Michael E. Castagna Pharm.D. is the chief executive officer of MannKind Corporation, which has about 591 employees.

Has MNKD ever split its stock?

Yes. The most recent MNKD stock split was a 1-for-5 split on Mar 3, 2017.

What is the MNKD 52-week high?

The 52-week high for MNKD is $6.51 and the 52-week low is $2.23. The stock is currently 40.9% below its high.

Compare MNKD